These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21873174)

  • 1. Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA.
    Hikita S; Yotsumoto F; Fukami T; Horiuchi S; Sanui A; Miyata K; Nam SO; Tsujioka H; Ueda T; Shirota K; Yoshizato T; Maeda K; Ishikawa T; Okuno Y; Kuroki M; Mekada E; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2553-9. PubMed ID: 21873174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer.
    Yagi H; Miyamoto S; Tanaka Y; Sonoda K; Kobayashi H; Kishikawa T; Iwamoto R; Mekada E; Nakano H
    Br J Cancer; 2005 May; 92(9):1737-45. PubMed ID: 15827558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
    Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
    Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells.
    Koshikawa N; Mizushima H; Minegishi T; Eguchi F; Yotsumoto F; Nabeshima K; Miyamoto S; Mekada E; Seiki M
    Cancer Sci; 2011 Jan; 102(1):111-6. PubMed ID: 20946474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
    Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
    Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
    Hazelton D; Nicosia RF; Nicosia SV
    Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma heparin-binding EGF-like growth factor levels in patients after partial hepatectomy as determined with an enzyme-linked immunosorbent assay.
    Yamada A; Kawata S; Tamura S; Kiso S; Higashiyama S; Umeshita K; Sakon M; Taniguchi N; Monden M; Matsuzawa Y
    Biochem Biophys Res Commun; 1998 May; 246(3):783-7. PubMed ID: 9618289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
    Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High concentrations of activin A in the peritoneal fluid of women with epithelial ovarian cancer.
    Cobellis L; Reis FM; Luisi S; Danero S; Pirtoli L; Scambia G; Petraglia F
    J Soc Gynecol Investig; 2004 May; 11(4):203-6. PubMed ID: 15120692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation.
    Di Simone N; Marana R; Castellani R; Di Nicuolo F; D'Alessio MC; Raschi E; Borghi MO; Chen PP; Sanguinetti M; Caruso A; Meroni PL
    Arthritis Rheum; 2010 May; 62(5):1504-12. PubMed ID: 20131286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer.
    Onsrud M; Shabana A; Austgulen R; Nustad K
    Gynecol Oncol; 1995 May; 57(2):183-7. PubMed ID: 7729731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in retinal gene expression in proliferative vitreoretinopathy: glial cell expression of HB-EGF.
    Hollborn M; Tenckhoff S; Jahn K; Iandiev I; Biedermann B; Schnurrbusch UE; Limb GA; Reichenbach A; Wolf S; Wiedemann P; Kohen L; Bringmann A
    Mol Vis; 2005 Jun; 11():397-413. PubMed ID: 15988409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production.
    Keay S; Kleinberg M; Zhang CO; Hise MK; Warren JW
    J Urol; 2000 Dec; 164(6):2112-8. PubMed ID: 11061938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
    Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
    Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
    Wahlberg K; Høyer-Hansen G; Casslén B
    Cancer Res; 1998 Aug; 58(15):3294-8. PubMed ID: 9699658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic protein expression in advanced epithelial ovarian cancer.
    Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
    Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.